Reimagining the future of healthcare
ASHLEY / Huntington’s Disease Community Advocate
Spotlight: uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AMT-130 in Huntington’s Disease
Press Releases
Subscribe to receive breaking news alerts about uniQure.
Subscribe-
-
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
-
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease